AMICUS THERAPEUTICS, INC. (FOLD)

8.24 0.13 (1.6%)

As of 2025-10-16 17:29:45 EST

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

Traded asNasdaq: FOLD
ISINUS03152W1099
CIK0001178879
LEI549300MRD1SMUTNBPQ53
EIN200422823
SectorBiotechnology
IndustryPharmaceutical Preparations
CEO—
Employees508
Fiscal Year End1231
Address47 HULFISH STREET, PRINCETON, NJ, 08542
Phone(609) 662-2000
Websitehttps://www.amicusrx.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
FOLDAMICUS THERAPEUTICS, INC.2025-10-16 17:29:458.240.131.6
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
FOLD0001178879AMICUS THERAPEUTICS, INC.US03152W1099549300MRD1SMUTNBPQ53200422823Nasdaq2834Pharmaceutical Preparations1231DE47 HULFISH STREETPRINCETONNJ08542UNITED STATESUS(609) 662-200047 HULFISH STREET, PRINCETON, NJ, 0854247 HULFISH STREET, PRINCETON, NJ, 08542AMICUS THERAPEUTICS INCBiotechnology2002-02-04—508https://www.amicusrx.com/2,940,574,460308,064,329308,239,374Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.2025-10-10 20:37:10
This is a preview of the latest data. Subscribe to access the full data.
FOLD Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
FOLD Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20242,940,574,460-616,374,057-17.3287300,116,0814,733,4671.6025
20233,556,948,517577,125,13119.3678295,382,61412,667,8764.4808
20222,979,823,386439,207,79717.2875282,714,7382,685,3930.959
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Ellen S. RosenbergChief Legal Officer, Corporate Secretary2024514,423332,8862,048,280—40,4753,800,307
David M. ClarkChief People Officer2024482,903270,1971,564,136—38,0063,015,209
Bradley L. CampbellChief Executive Officer, President2024767,308623,7004,990,365—39,9438,526,943
Simon HarfordChief Financial Officer2024514,423275,3191,862,083—11,5623,449,065
Jeffrey P. CastelliChief Development Officer2024491,807263,4941,862,083—39,8343,442,896
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024499
2023517
2022484
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue528,295,000399,356,000329,233,000
Cost Of Revenue52,943,00037,326,00038,599,000
Gross Profit475,352,000362,030,000290,634,000
Research And Development Expenses109,362,000152,381,000276,677,000
General And Administrative Expenses323,379,000275,270,000213,041,000
Operating Expenses450,476,000439,241,000502,754,000
Operating Income24,876,000-77,211,000-212,120,000
Net Income-56,106,000-151,584,000-236,568,000
Earnings Per Share Basic-0.18-0.51-0.82
Earnings Per Share Diluted-0.18-0.51-0.82
Weighted Average Shares Outstanding Basic304,380,502295,164,515289,057,198
Weighted Average Shares Outstanding Diluted304,380,502295,164,515289,057,198
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents213,752,000246,994,000148,813,000
Marketable Securities Current36,194,00039,206,000144,782,000
Accounts Receivable101,099,00087,632,00066,196,000
Inventories118,782,00059,696,00023,816,000
Non Trade Receivables———
Other Assets Current———
Total Assets Current504,736,000483,061,000423,816,000
Marketable Securities Non Current———
Property Plant And Equipment29,383,00031,667,00030,778,000
Other Assets Non Current13,641,00018,553,00019,242,000
Total Assets Non Current280,297,000294,819,000300,351,000
Total Assets785,033,000777,880,000724,167,000
Accounts Payable12,947,00015,120,00015,413,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current———
Total Liabilities Current148,702,000167,689,000139,018,000
Long Term Debt390,111,000387,858,000391,990,000
Other Liabilities Non Current7,097,00013,282,0008,939,000
Total Liabilities Non Current442,286,000450,017,000462,102,000
Total Liabilities590,988,000617,706,000601,120,000
Common Stock2,944,0002,918,0002,815,000
Retained Earnings-2,740,180,000-2,684,074,000-2,532,490,000
Accumulated Other Comprehensive Income———
Total Shareholders Equity194,045,000160,174,000123,047,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization8,547,0007,873,0005,342,000
Share Based Compensation Expense84,905,00086,077,00076,512,000
Other Non Cash Income Expense———
Change In Accounts Receivable19,484,00020,108,00017,330,000
Change In Inventories73,652,00044,614,0005,343,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-16,520,00049,195,000-6,377,000
Change In Other Liabilities———
Cash From Operating Activities-33,891,000-69,091,000-166,575,000
Purchases Of Marketable Securities114,786,00091,723,000243,255,000
Sales Of Marketable Securities117,779,000197,227,000335,926,000
Acquisition Of Property Plant And Equipment3,553,0007,440,0003,766,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-560,00098,064,00092,316,000
Tax Withholding For Share Based Compensation22,025,00017,920,00011,490,000
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt0408,043,0000
Other Financing Activities———
Cash From Financing Activities5,121,00061,677,000-7,463,000
Change In Cash-33,361,00096,962,000-96,341,000
Cash At End Of Period213,752,000246,994,000148,813,000
Income Taxes Paid8,214,0008,525,0001,609,000
Interest Paid58,960,00036,090,00034,358,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-0.18-0.51-0.82
Price To Earnings Ratio-52.3333-27.8235-14.8902
Earnings Growth Rate-64.7059-37.8049-10.8696
Price Earnings To Growth Ratio0.80880.7361.3699
Book Value Per Share0.63750.54270.4257
Price To Book Ratio14.776326.14928.6833
Ebitda10,253,000-85,037,000-192,498,000
Enterprise Value3,043,623,328.844,329,248,467.853,772,565,387.58
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio2.01042.42153.1857
Capital Expenditures6,263,0008,762,000-6,376,000
Free Cash Flow-40,154,000-77,853,000-160,199,000
Return On Equity-0.2891-0.9464-1.9226
One Year Beta1.02050.83191.1579
Three Year Beta1.06231.07721.283
Five Year Beta1.22591.25271.3172
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Harford Simon N.R.Chief Financial Officer2025-08-2112,529D214,898
WHEELER CRAIG ADirector2025-06-0574,872A74,872
Bleil Lynn DorseyDirector2025-06-0520,414A113,941
Bleil Lynn DorseyDirector2025-06-0574,872A74,872
ROBERTS EIRYDirector2025-06-0520,414A76,275
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Daniel Goldman2023-05-19NY10Sale2023-04-10—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
RICE HALL JAMES & ASSOCIATES, LLC2025-09-3027,065,5703,434,7177.88
CWM, LLC2025-09-30286,00036,3127.8762
Inspire Investing, LLC2025-09-30454,22857,6437.88
Farther Finance Advisors, LLC2025-09-30536687.8824
WEDGE CAPITAL MANAGEMENT L L P/NC2025-09-301,051,791133,4767.88
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Elevation Series Trust2025-07-31Sovereign's Capital Flourish FundSOVF399,0562,390,345.442.0889
ETFis Series Trust I2025-07-31Virtus LifeSci Biotech Products ETFBBP72,025431,429.751.7505
INVESCO EXCHANGE-TRADED FUND TRUST2025-07-31Invesco RAFI US 1500 Small-Mid ETFPRFZ175,4751,051,095.250.0443
Global X Funds2025-07-31Global X Guru Index ETFGURU95,338571,074.621.1215
Global X Funds2025-07-31Global X Russell 2000 ETFRSSL142,456853,311.440.0649
This is a preview of the latest data. Subscribe to access the full data.